Tandem Diabetes Care (TNDM) Could Be 45% Undervalued After Tandem Mobi Europe Launch
How the Tandem Mobi rollout frames Tandem Diabetes Care today
Tandem Diabetes Care (TNDM) has widened access to its Tandem Mobi automated insulin delivery system by opening orders in 12 countries across Europe and the UK for eligible users.
The product relies on Control IQ+ technology and Dexcom G7 integration to automate insulin dosing, offers multiple wear options and iPhone app control, and targets people managing type 1 or type 2 diabetes outside the US.
Tandem Diabetes Care has paired this broader Tandem Mobi rollout with a mixed trading pattern, where the share price is up 4.54% over 90 days but down 15.70% over 30 days, and total shareholder return sits at 15.07% over one year. This points to momentum that has cooled recently despite a better longer run for holders.
Scan beyond Tandem Diabetes Care and see how other diabetes and healthcare device stocks are positioned with our hand picked 34 healthcare AI stocks list for this theme.
Bulls point to Tandem Diabetes Care’s growing Mobi footprint and recent profit momentum. Bears focus on the share price slide and ongoing losses. Which side does the current valuation support more strongly?
Most Popular Narrative: 45% Undervalued
The most followed narrative values Tandem Diabetes Care at $29.20 a share, well above the last close of $16.11, which puts the focus squarely on whether its pump ecosystem can carry the story.
Broader pharmacy channel expansion and acceleration of pharmacy-based supply sales are expected to lower out-of-pocket costs, increase pump adoption rates, and shift more high-margin recurring supply sales through premium-priced channels. This is described as supporting future revenue growth, margin expansion, and improved earnings.
See why 7 investors see Tandem Diabetes Care as 45% undervalued.
Result: Fair Value of $29.20 (UNDERVALUED)
Still, rising competition in insulin pumps and execution risk around the pharmacy rollout could quickly weaken the Tandem Diabetes Care earnings story that analysts are modeling.
Find out about the key risks to this Tandem Diabetes Care narrative.
Next Steps
Sentiment around Tandem Diabetes Care is clearly split, so move quickly from headline opinions to your own read by stress testing the positives in its profile using 3 key rewards
Looking for more Tandem Diabetes Care investment ideas?
If Tandem Diabetes Care has your attention, broaden your watchlist now so you are not relying on a single stock to carry your thesis.
Use the Simply Wall St screener to pressure test your thinking across different styles of opportunities before the next wave of moves plays out.
- Target potential mispricings by scanning a curated set of companies that look underappreciated on quality and valuation using 28 high quality undervalued stocks.
- Prioritise resilience by focusing on businesses with sturdier finances through a dedicated list of solid balance sheet and fundamentals (25 results) that filters for stronger balance sheets and fundamentals.
- Hunt for off-the-radar opportunities by reviewing a focused pool of 20 high quality undiscovered gems that may not yet be widely followed.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com